IP Library › Granted Patent US 9,783,614
Granted Patent B2
US 9,783,614 · App. 14/400,281 · Granted Oct 10, 2017

Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof

Inventors: Andreas Wilmen (Cologne, DE); Julia Straβburger (Wuppertal, DE); Frank Dittmer (Düsseldorf, DE); Michael Strerath (Düsseldorf, DE); Anja Buchmüller (Essen, DE); Joanna Grudzinska-Goebel (Berlin, DE); Ricarda Finnern (Aachen, DE); Martina Schäfer (Berlin, DE); Christoph Gerdes (Köln, DE); Hannah Jöriβen (Heiligenhaus, DE); Asako Itakura (Portland, OR); Philberta Leung (Portland, OR); Erik Tucker (Portland, OR)
Assignee: Bayer Pharma Aktiengesellschaft
C07K16/36A61K2039/505C07K2317/24C07K2317/56C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,783,614
App. No.
14/400,281
Granted
Oct 10, 2017
Kind
B2
Abstract

The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.

Claims (6)

1. Human monoclonal antibodies capable of binding to coagulation Factor XIa comprising SEQ ID NO: 27 for the amino acid sequence for the variable light chain domain and SEQ ID NO: 20 for the amino acid sequence for the variable heavy chain domain.

2. A pharmaceutical composition comprising an antibody of claim 1 .

3. The human monoclonal antibodies according to claim 1 , wherein said antibody is a human IgG1 antibody.

4. Human monoclonal antibodies capable of binding to coagulation Factor XIa comprising as CDRH1 SEQ ID NO: 21, as CDRH2 SEQ ID NO: 22 and as CDRH3 SEQ ID NO: 23 and as CDRL1 SEQ ID NO: 24, as CDRL2 SEQ ID NO: 25 and as CDRL3 SEQ ID NO: 28.

5. A pharmaceutical composition comprising an antibody of claim 4 .

6. The human monoclonal antibodies according to claim 4 , wherein said antibody is a human IgG1 antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2015
From: WILMEN, ANDREAS, DR; STRASSBURGER, JULIA; DITTMER, FRANK, DR; STRERATH, MICHAEL, DR; BUCHMÜLLER, ANJA, DR; GRUDZINSKA-GOEBEL, JOANNA L, DR; FINNERN, RICARDA, DR; SCHÄFER, MARTINA, DR; GERDES, CHRISTOPH, DR; JÖRISSEN, HANNAH, DR; ITAKURA, ASAKO, DR; LEUNG, PHILBERTA Y; TUCKER, ERIK
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 035658/0313 →
Priority Claims (3)
EP 12167438 · May 10, 2012 · regional
EP 12181697 · Aug 24, 2012 · regional
EP 13150361 · Jan 7, 2013 · regional
Continuity (2)
Provisional Application 61817675 · Apr 30, 2013
Related Publication 20150099298A1 · Apr 9, 2015